Tonix Pharma (TNXP) Price & Analysis

Q: What was Tonix Pharmaceuticals’s price range in the past 12 months?

Tonix Pharmaceuticals lowest stock price was $6.76 and its highest was $130.35 in the past 12 months.

Q: What is Tonix Pharmaceuticals’s market cap?

Tonix Pharmaceuticals’s market cap is $197.90M.

Q: When is Tonix Pharmaceuticals’s upcoming earnings report date?

Tonix Pharmaceuticals’s upcoming earnings report date is Mar 16, 2026 which is in 116 days.

Q: How were Tonix Pharmaceuticals’s earnings last quarter?

Tonix Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$3.59 earnings per share for the quarter, missing the consensus estimate of -$3.585 by -$0.005.

Q: Is Tonix Pharmaceuticals overvalued?

According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Tonix Pharmaceuticals pay dividends?

Tonix Pharmaceuticals does not currently pay dividends.

Q: What is Tonix Pharmaceuticals’s EPS estimate?

Tonix Pharmaceuticals’s EPS estimate is -4.18.

Q: How many shares outstanding does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals has 11,776,542 shares outstanding.

Q: What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?

Tonix Pharmaceuticals reported an EPS of -$3.59 in its last earnings report, missing expectations of -$3.585. Following the earnings report the stock price went up 4.097%.

Q: Which hedge fund is a major shareholder of Tonix Pharmaceuticals?

Currently, no hedge funds are holding shares in TNXP

Compare

4,993 Followers

TNXP Stock Chart & Stats

$19.84

-$0.02(-7.15%)

At close: Jan 08 4:00 PM EST

$19.84

-$0.02(-7.15%)

Day’s Range― - ―

52-Week Range$6.76 - $130.35

Previous CloseN/A

Volume36.66M

Average Volume (3M)775.37K

Market Cap

$197.90M

Enterprise Value$25.94M

Total Cash (Recent Filing)$190.06M

Total Debt (Recent Filing)$425.00K

Price to Earnings (P/E)―

Beta1.82

Next Earnings

Mar 16, 2026

EPS Estimate

-4.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.59

Shares Outstanding11,776,542

10 Day Avg. Volume732,093

30 Day Avg. Volume775,374

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.53

Price to Sales (P/S)7.40

P/FCF Ratio-1.22

Enterprise Value/Market Cap0.13

Enterprise Value/Revenue2.52

Enterprise Value/Gross Profit7.34

Enterprise Value/Ebitda-0.27

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-14.48

Revenue Forecast (FY)$9.60M

Tonix Pharma News

Tonix Pharmaceuticals announces U.S. commercial availability of TONMYA

Tonix Pharmaceuticals (TNXP) announced that TONMYATM is now commercially available at pharmacies by prescription in the United States....

3d ago

TNXP

Tonix Pharmaceuticals announces collaboration with MGH

Tonix Pharmaceuticals (TNXP) announced a collaboration with Massachusetts General Hospital, MGH, a founding member of Mass General Brigham,...

16d ago

TNXP

Tonix Pharmaceuticals presents data on Tonmya at ACR Convergence

Tonix Pharmaceuticals (TNXP) presented data on Tonmya, which was investigated as TNX-102 SL, at the 2025 American College...

24d ago

TNXP

Tonix Pharmaceuticals announces first patient dosed in FOCUS study at MGH

Tonix Pharmaceuticals (TNXP) announced that the first patient has been dosed in the investigator-initiated FOCUS study at Massachusetts...

29d ago

TNXP

Tonix Pharma Expands Share Repurchase Program

Tonix Pharma ( ($TNXP) ) has issued an announcement. On November 18, 2025, Tonix Pharmaceuticals Holding Corp. announced...

2d ago

TNXP

Tonix Pharma Launches TONMYA Tablets in U.S.

An announcement from Tonix Pharma ( ($TNXP) ) is now available. On November 17, 2025, Tonix Pharmaceuticals announced...

3d ago

TNXP

Tonix Pharmaceuticals Reports Q3 2025 Earnings and Strategic Developments

Tonix Pharmaceuticals ( ($TNXP) ) has released its Q3 earnings. Here is a breakdown of the information Tonix...

9d ago

TNXP

Tonix Pharmaceuticals (TNXP) Q3 Earnings Cheat Sheet

Tonix Pharmaceuticals (TNXP) is scheduled to report 3rd quarter earnings on 11/10/2025. Regarding Q3 estimates, Wall Street analysts...

12d ago

TNXP

Tonix Pharma Begins FOCUS Study on AVP-D Treatment

The latest update is out from Tonix Pharma ( ($TNXP) ). On October 22, 2025, Tonix Pharmaceuticals announced...

29d ago

TNXP

Tonix Pharmaceuticals presents data on TNX-801 Mpox vaccine

Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the World Vaccine Congress-Europe 2025, held October 14-16,...

1M ago

TNXP

Tonix presents update on TNX-1500 at Japan Society for Transplantation

Tonix Pharmaceuticals (TNXP) announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, delivered a presentation titled...

1M ago

TNXP

Tonix Pharma Plans Phase 2 Trial for 2026

Tonix Pharma ( ($TNXP) ) has provided an update. Tonix Pharmaceuticals announced plans to initiate a Phase 2...

1M ago

TNXP

Tonix Pharma Appoints New Head of Market Access

Tonix Pharma ( ($TNXP) ) has shared an announcement. On September 30, 2025, Tonix Pharmaceuticals announced the appointment...

2M ago

TNXP

Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access

Tonix Pharmaceuticals (TNXP) Holding announced the appointment of Ganesh Kamath as Head of Market Access, effective September 29,...

2M ago

TNXP

TNXP FAQ

What was Tonix Pharmaceuticals’s price range in the past 12 months?

Tonix Pharmaceuticals lowest stock price was $6.76 and its highest was $130.35 in the past 12 months.

What is Tonix Pharmaceuticals’s market cap?

Tonix Pharmaceuticals’s market cap is $197.90M.

When is Tonix Pharmaceuticals’s upcoming earnings report date?

Tonix Pharmaceuticals’s upcoming earnings report date is Mar 16, 2026 which is in 116 days.

How were Tonix Pharmaceuticals’s earnings last quarter?

Tonix Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$3.59 earnings per share for the quarter, missing the consensus estimate of -$3.585 by -$0.005.

Is Tonix Pharmaceuticals overvalued?

According to Wall Street analysts Tonix Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tonix Pharmaceuticals pay dividends?

Tonix Pharmaceuticals does not currently pay dividends.

What is Tonix Pharmaceuticals’s EPS estimate?

Tonix Pharmaceuticals’s EPS estimate is -4.18.

How many shares outstanding does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals has 11,776,542 shares outstanding.

What happened to Tonix Pharmaceuticals’s price movement after its last earnings report?

Tonix Pharmaceuticals reported an EPS of -$3.59 in its last earnings report, missing expectations of -$3.585. Following the earnings report the stock price went up 4.097%.

Which hedge fund is a major shareholder of Tonix Pharmaceuticals?

Currently, no hedge funds are holding shares in TNXP

Tonix Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.99%

Trailing 12-Months

Asset Growth

165.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system disorders, immunology, and infectious diseases. The company is engaged in the research, development, and commercialization of novel therapeutics, including vaccines and other biologics that address significant unmet medical needs. Tonix's core products include TNX-102 SL, a sublingual formulation of cyclobenzaprine for fibromyalgia, and a range of vaccine candidates aimed at addressing various infectious diseases.